Companies Cartesian Therapeutics, Inc.
Cartesian Therapeutics CEO salary & total pay, FY2025: $4.3M
Cartesian Therapeutics (RNAC) CEO salary, fiscal 2025: Carsten Brunn was paid a salary of $674,000 and $4,329,868 in total compensation. Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Cartesian Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
Carsten Brunn's complete compensation dossier
A PDF and a CSV sent to your email: Carsten Brunn's pay in every fiscal year Cartesian Therapeutics, Inc. reported it, line by line, with Carsten Brunn's equity grants and Cartesian Therapeutics, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.
See an example →CEO pay, last three years
- $6,111,883FY2023
- $7,314,211FY2024
- $4,329,868FY2025
CEO total pay was $4,329,868 in fiscal 2025, down from $7,314,211 in fiscal 2024.
FY2025: salary $674,000 · bonus $0 · stock awards $973,475 · option awards $2,314,320
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Carsten Brunn | $674,000 | $0 | $973,475 | $2,314,320 | $363,960 | $0 | $4,113 | $4,329,868 |
| President and Chief Executive Officer | ||||||||
| Metin Kurtoglu | 163,494 | 0 | 775,931 | 984,442 | 60,427 | 0 | 489,740 | 2,474,034 |
| Former Chief Technology Officer | ||||||||
| Christopher Jewell | 390,665 | 0 | 375,046 | 661,814 | 144,200 | 0 | 443,982 | 2,015,707 |
| Former Chief Scientific Officer | ||||||||
| Blaine Davis | 475,860 | 0 | 372,460 | 884,122 | 205,572 | 0 | 11,913 | 1,949,927 |
| Chief Financial Officer | ||||||||
| Milos Miljkovic | 439,000 | 0 | 321,670 | 766,422 | 118,530 | 0 | 11,913 | 1,657,535 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Carsten Brunn | $4,329,868 | $7,314,211 | $6,111,883 | ↓ −2,984,343 |
| Metin Kurtoglu | 2,474,034 | 2,713,064 | 71,243 | ↓ −239,030 |
| Christopher Jewell | 2,015,707 | 1,687,754 | — | ↑ +327,953 |
| Blaine Davis | 1,949,927 | 3,971,412 | 2,494,759 | ↓ −2,021,485 |
| Milos Miljkovic | 1,657,535 | 1,349,018 | — | ↑ +308,517 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company designs its executive compensation program to reward performance consistent with strategic and financial results, emphasizing variable pay over fixed pay to attract, retain, and motivate top talent. The program balances short-term and long-term incentives, with a significant portion of target total direct compensation delivered in equity awards to align executive interests with long-term stockholder value creation.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Exercisable | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|---|
| Blaine Davis | Option | 25,917 | 77,749 | 19.66 | — |
| Blaine Davis | RSU | — | 60,600 | — | 436,926 |
| Blaine Davis | Option | — | 64,600 | 16.93 | — |
| Blaine Davis | RSU | — | 22,000 | — | 158,620 |
| Carsten Brunn | Option | 49,759 | 149,274 | 19.66 | — |
| Carsten Brunn | RSU | — | 116,352 | — | 838,898 |
| Carsten Brunn | Option | — | 169,100 | 16.93 | — |
| Carsten Brunn | RSU | — | 57,500 | — | 414,575 |
| Christopher Jewell | Option | 8,317 | 24,948 | 19.66 | — |
| Christopher Jewell | RSU | — | 19,455 | — | 140,271 |
| Christopher Jewell | Option | — | 47,400 | 16.93 | — |
| Christopher Jewell | RSU | — | 16,100 | — | 116,081 |
| Christopher Jewell | Option | 67,432 | — | 3.23 | — |
| Metin Kurtoglu | Option | 10,690 | 3,564 | 3.23 | — |
| Metin Kurtoglu | Option | — | 47,400 | 16.93 | — |
| Metin Kurtoglu | RSU | — | 16,100 | — | 116,081 |
| Metin Kurtoglu | Option | 79,099 | — | 1.41 | — |
| Metin Kurtoglu | Option | 14,254 | — | 3.23 | — |
| Metin Kurtoglu | Option | 65,499 | — | 19.66 | — |
| Milos Miljkovic | Option | 5,859 | 17,574 | 19.66 | — |
| Milos Miljkovic | RSU | — | 13,704 | — | 98,806 |
| Milos Miljkovic | Option | — | 56,000 | 16.93 | — |
| Milos Miljkovic | RSU | — | 19,000 | — | 136,990 |
| Milos Miljkovic | Option | 30,528 | — | 3.23 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Carrie S. CoxIndependent · Compensation · Departed during FY | $82,880 | $44,018 | $103,635 | — | $0 | $230,533 |
| Patrick Zenner, M.B.AIndependent · Lead Independent Director · Audit · Compensation · Nominating and Corporate Governance (Chair) | 71,848 | 44,018 | 101,044 | — | 0 | 216,910 |
| Timothy C. Barabe, M.B.AIndependent · Audit (Chair) · Compensation · Nominating and Corporate Governance | 65,000 | 44,018 | 101,044 | — | 0 | 210,062 |
| Murat Kalayoglu, M.D., Ph.DIndependent · Departed during FY | 58,836 | 44,018 | 101,044 | — | 0 | 203,898 |
| Nishan de Silva, M.D., M.B.AIndependent · Audit · Compensation | 57,500 | 44,018 | 101,044 | — | 0 | 202,562 |
| Kemal Malik, M.B.B.SIndependent · Compensation (Chair) · Science and Technology | 56,304 | 44,018 | 101,044 | — | 0 | 201,366 |
| Michael Singer, M.D., Ph.DIndependent · Nominating and Corporate Governance · Science and Technology | 52,500 | 44,018 | 101,044 | — | 0 | 197,562 |
| Timothy A. Springer, Ph.DIndependent · Nominating and Corporate Governance · Science and Technology | 47,500 | 44,018 | 101,044 | — | 0 | 192,562 |
| Adrian Bot, M.D., Ph.DIndependent · Science and Technology (Chair) | 2,065 | 48,082 | 108,960 | — | 0 | 159,107 |
| Carsten Brunn, Ph.DEmployee director · Board Chair | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $494,433 |
| Equity awards (grant-date value) | $400,226 |
| All other compensation | $0 |
| Total cost of the board | $894,659 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Cartesian Therapeutics as a peer
Companies that benchmark against RNAC
1 company names RNAC as a compensation peer
- Generation Bio Co.GBIOFY2024
- LEXICON PHARMACEUTICALS, INC.LXRXFY2025
- Lineage Cell Therapeutics, Inc.LCTXFY2025
- Seres Therapeutics, Inc.MCRBFY2025
Each company listed discloses RNAC in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named RNAC in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Peer reciprocity
The companies Cartesian Therapeutics, Inc. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Vor Biopharma | 2025 | Jean-Paul Kress | $344,615 | $0 | $64,013,465 | $251,425 | $65,027,569 |
| 2 | Cogent Biosciences | 2025 | Andrew Robbins | 724,554 | 12,993,250 | 13,447,680 | 561,600 | 27,762,684 |
| 3 | MeiraGTx Holdings | 2025 | Alexandria Forbes | 840,000 | 5,823,500 | — | — | 8,330,006 |
| 4 | Corvus Pharmaceuticals | 2025 | Richard Miller | 36,566 | 0 | 6,989,000 | 0 | 7,031,566 |
| 5 | Viridian Therapeutics | 2025 | Stephen Mahoney | 700,000 | 1,058,098 | 4,381,713 | 630,000 | 6,776,249 |
| 6 | Allogene Therapeutics | 2025 | David Chang | 724,000 | 2,409,537 | 2,588,329 | 400,010 | 6,136,093 |
| 7 | AnaptysBio | 2025 | Daniel Faga | 706,011 | 1,592,001 | 3,345,653 | 465,968 | 6,133,943 |
| 8 | Replimune Group | 2026 | Sushil Patel | 700,000 | 3,376,003 | 1,448,325 | 315,000 | 5,845,982 |
| 9 | Rezolute | 2026 | Nevan Charles Elam | 655,000 | 3,220,720 | 1,358,972 | 0 | 5,711,410 |
| 10 | Candel Therapeutics | 2025 | Paul Peter Tak | 743,592 | 0 | 3,916,028 | 396,653 | 5,344,561 |
| 11 | Savara | 2025 | Matthew Pauls | 660,000 | 3,870,000 | 0 | 297,000 | 4,845,000 |
| 12 | Cartesian Therapeutics, Inc. | 2025 | Carsten Brunn | 674,000 | 973,475 | 2,314,320 | 363,960 | 4,329,868 |
| 13 | Regenxbio | 2025 | Curran Simpson | 665,510 | 777,448 | 2,350,302 | 387,327 | 4,200,712 |
| 14 | Annexon | 2025 | Douglas Love | 670,833 | 0 | 2,522,260 | 371,250 | 3,579,202 |
| 15 | Rocket Pharmaceuticals | 2025 | Gaurav Shah | 671,076 | 806,751 | 1,613,377 | 403,048 | 3,510,241 |
| 16 | Cabaletta Bio | 2025 | Steven Nichtberger | 659,550 | 0 | 1,266,978 | 446,982 | 2,401,555 |
| 17 | Lineage Cell Therapeutics | 2025 | Brian Culley | 691,800 | 0 | 882,970 | 518,900 | 2,111,170 |
| 18 | MacroGenics | 2025 | Eric Risser | 561,568 | 52,000 | 1,049,386 | 251,900 | 2,078,854 |
| 19 | 4D Molecular Therapeutics | 2025 | David Kirn | 667,252 | 0 | 822,750 | 560,597 | 2,051,343 |
| 20 | Alector | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Cartesian Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Compensia |
| 4D Molecular Therapeutics | 140% | Options 100 | not disclosed | Radford (part of the Rewards Solutions practice at Aon plc) |
| Alector | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Allogene Therapeutics | not disclosed | Option 55 · RSU 25 · PSU 20 | not disclosed | Compensia |
| AnaptysBio | 110% | not disclosed | No | Alpine Rewards |
| Annexon | 100% of target% | not disclosed | not disclosed | Alpine Rewards |
| Cabaletta Bio | not disclosed | Option 100 | not disclosed | Aon |
| Candel Therapeutics | not disclosed | not disclosed | not disclosed | Aon Plc d/b/a Radford |
| Cogent Biosciences | 135% | not disclosed | No | Compensia |
| Corvus Pharmaceuticals | not disclosed | Option 100 | not disclosed | not disclosed |
| Lineage Cell Therapeutics | not disclosed | not disclosed | not disclosed | Anderson |
| MacroGenics | 85% | not disclosed | not disclosed | Alpine Rewards, LLC |
| MeiraGTx Holdings | not disclosed | RSU 100 | not disclosed | Total Compensation Solutions |
| Regenxbio | 97% | Options 75 · RSU 25 | not disclosed | Willis Towers Watson |
| Replimune Group | 92.5% | not disclosed | No | Pearl Meyer |
| Rezolute | 50% | not disclosed | not disclosed | not disclosed |
| Rocket Pharmaceuticals | not disclosed | not disclosed | not disclosed | Semler Brossy |
| Savara | 90% | RSU 100 | not disclosed | Aon |
| Viridian Therapeutics | 150% | Options 75 · RSU 25 | not disclosed | Compensia |
| Vor Biopharma | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-12 | 13,659,709 | 136,217 | 6,033,199 | 99.01% | Passed |
| 2025 | 2025-06-13 | 19,701,123 | 157,132 | 1,726 | 99.21% | Passed |
| 2023 | 2023-06-16 | 63,731,591 | 5,090,940 | 1,074,196 | 92.6% | Passed |
| 2022 | 2022-06-17 | 59,419,306 | 3,352,586 | 2,678,803 | 94.66% | Passed |
| 2021 | 2021-06-18 | — | — | — | — | — |
| 2020 | 2020-06-19 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-12 | 99.01%a |
| 2025 | 2025-06-13 | 99.21%b |
| 2023 | 2023-06-16 | 92.6%c |
a. Approved under the standard stated in the filing — “Proposal 2: Approval of Compensation of Named Executive Officers -- The affirmative vote of the holders of a majority in voting power of the votes cast. | Abstentions: Abstentions and broker non-votes will have no effect.”.
b. Approved under the standard stated in the filing — “Proposal 2: Approval of Compensation of Named Executive Officers -- The affirmative vote of the holders of a majority in voting power of the votes cast. | Abstentions: Abstentions and broker non-votes will have no effect.”.
c. Approved under the standard stated in the filing — “Proposal 2: Approval of Compensation of Named Executive Officers -- The affirmative vote of the holders of a majority in voting power of the votes cast. | Abstentions: Abstentions and broker non-votes will have no effect.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (41 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Carsten Brunn. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · page 38. As printed: 4,329,868. View filing ↗
- Section 01, Metin Kurtoglu. DEF 14A, filed 2026-04-28. Section “Executive Compensation”. As printed: 2,474,034. View filing ↗
- Section 01, Christopher Jewell. DEF 14A, filed 2026-04-28. Section “Executive Compensation”. As printed: 2,015,707. View filing ↗
- Section 01, Blaine Davis. DEF 14A, filed 2026-04-28. Section “Executive Compensation”. As printed: 1,949,927. View filing ↗
- Section 01, Milos Miljkovic. DEF 14A, filed 2026-04-28. Section “Executive Compensation”. As printed: 1,657,535. View filing ↗
- Section 08, Carrie S. Cox. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 230,533. View filing ↗
- Section 08, Patrick Zenner, M.B.A. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 216,910. View filing ↗
- Section 08, Timothy C. Barabe, M.B.A. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 210,062. View filing ↗
- Section 08, Murat Kalayoglu, M.D., Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 203,898. View filing ↗
- Section 08, Nishan de Silva, M.D., M.B.A. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 202,562. View filing ↗
- Section 08, Kemal Malik, M.B.B.S. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 201,366. View filing ↗
- Section 08, Michael Singer, M.D., Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 197,562. View filing ↗
- Section 08, Timothy A. Springer, Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 192,562. View filing ↗
- Section 08, Adrian Bot, M.D., Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 159,107. View filing ↗
- Section 08, Carsten Brunn, Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-17. Item 5.07 · say-on-pay result. As reported: 99.01% (votes for as printed: 13,659,709). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-16. Item 5.07 · say-on-pay result. As reported: 99.21% (votes for as printed: 19,701,123). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-16. Item 5.07 · say-on-pay result. As reported: 92.6% (votes for as printed: 63,731,591). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 494,433 + equity 400,226 + all other 0 = 894,659, summed across the director compensation table rows.
- Vor Biopharma, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Vor Biopharma's own proxy. As printed: 65,027,569. View filing ↗
- Cogent Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Cogent Biosciences's own proxy. As printed: 27,762,684. View filing ↗
- MeiraGTx Holdings, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in MeiraGTx Holdings's own proxy. As printed: 8,330,006. View filing ↗
- Corvus Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Corvus Pharmaceuticals's own proxy. As printed: 7,031,566. View filing ↗
- Viridian Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Viridian Therapeutics's own proxy. As printed: 6,776,249. View filing ↗
- Allogene Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Allogene Therapeutics's own proxy. As printed: 6,136,093. View filing ↗
- AnaptysBio, Section 10b CEO total. DEF 14A, filed 2026-06-29. CEO total compensation as printed in AnaptysBio's own proxy. As printed: 6,133,943. View filing ↗
- Replimune Group, Section 10b CEO total. DEF 14A, filed 2026-07-29. CEO total compensation as printed in Replimune Group's own proxy. As printed: 5,845,982. View filing ↗
- Rezolute, Section 10b CEO total. DEF 14A, filed 2026-10-21. CEO total compensation as printed in Rezolute's own proxy. As printed: 5,711,410. View filing ↗
- Candel Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Candel Therapeutics's own proxy. As printed: 5,344,561. View filing ↗
- Savara, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Savara's own proxy. As printed: 4,845,000. View filing ↗
- Cartesian Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Cartesian Therapeutics, Inc.'s own proxy. As printed: 4,329,868. View filing ↗
- Regenxbio, Section 10b CEO total. DEF 14A, filed 2026-04-14. CEO total compensation as printed in Regenxbio's own proxy. As printed: 4,200,712. View filing ↗
- Annexon, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Annexon's own proxy. As printed: 3,579,202. View filing ↗
- Rocket Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Rocket Pharmaceuticals's own proxy. As printed: 3,510,241. View filing ↗
- Cabaletta Bio, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Cabaletta Bio's own proxy. As printed: 2,401,555. View filing ↗
- Lineage Cell Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Lineage Cell Therapeutics's own proxy. As printed: 2,111,170. View filing ↗
- MacroGenics, Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in MacroGenics's own proxy. As printed: 2,078,854. View filing ↗
- 4D Molecular Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in 4D Molecular Therapeutics's own proxy. As printed: 2,051,343. View filing ↗
- Alector, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Alector's own proxy. As printed: 1,995,018. View filing ↗
- Section 10a, Lineage Cell Therapeutics reciprocity. DEF 14A. Lineage Cell Therapeutics names Cartesian Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗